Navigation Links
Pre-clinical data shows Angiocidin effective against leukemia

Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.

George P. Tuszynski, a professor of neuroscience in Temple University's School of Medicine who discovered Angiocidin, will present the findings during the American Society of Hematology's national meeting in Atlanta on Dec. 9.

AML causes certain white blood cells to stop maturing, resulting in their uncontrolled proliferation, which can lead to suppression of the immune system and often fatal secondary problems such as infections, including pneumonia, and an increased risk for bleeding.

In earlier in vitro studies using four AML cell lines and patient AML cells, Angiocidin demonstrated the ability to stimulate maturation in the affected white cells, causing them to behave and function like normal cells.

With 50 percent success in the in vitro patient studies, the researchers next focused on how Angiocidin would perform against cells from AML patients in vivo. Samples from a patient were injected into a special mouse model developed by Martin Carroll, associate professor of medicine at the University of Pennsylvania. Over a 14 week period, the leukemia cells engrafted to the bone marrow of the mice.

The mice were then given doses of Ara-C, Angiocidin or a combination of both. The chemotherapy agent Ara-C, or cytosine arabinoside, is standard-of-care for AML and kills cancer cells by inhibiting DNA synthesis.

Mice treated only with Angiocidin saw a 63 percent reduction in AML cells, while those treated with both experienced a 79 percent reduction in AML cells. Mice treated with Ara-C alone saw a reduction of only around 40 percent.

"One question we had is whether Angiocidin would be able to get into the bone marrow," said Tuszynski. "These results clearly show that Angiocidin is able to prevent the growth of AML cells in the bone marrow." However, Tuszynski cautioned that pre-clinical data is not always predictive of activity in humans.

While Ara-C and other drugs used to treat AML are highly toxic, Angiocidin has exhibited no evidence of toxicity, making it a potentially safer alternative treatment to standard-of-care, especially for elderly patients who can't tolerate chemotherapy.

Tuszynski said that additional pre-clinical tests are being performed to gather more data and to determine an optimal dose of Angiocidin for patients. "Once we have all of our pre-clinical data together, we will be able to begin preparing for a clinical trial in humans," he said.

The pre-clinical testing of Angiocidin has been funded through a grant from Philadelphia's University City Science Center.

A start-up company, Diffregen LLC, has licensed Angiocidin from Temple. They recently submitted a small business innovation research (SBIR) grant proposal to the National Institutes of Health to support product development activities for this novel treatment for AML and potentially other cancers.

Contact: Preston M. Moretz
Temple University

Related medicine news :

1. Wellesley study shows income inequality a key factor in high US teen births
2. Invasive heart test being dramatically overused, Stanford study shows
3. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
4. Lung Cancer Screening Might Pay Off, Analysis Shows
5. Nonsurgical Method to Measure Brain Pressure Shows Promise
6. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
7. Study Shows New Option for Kids With Tough-to-Treat Leukemia
8. Politics May Get in the Way of Empathy, Research Shows
9. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
10. Experimental Pill for Multiple Sclerosis Shows Promise
11. Mechanical tissue resuscitation technology shows promise
Post Your Comments:
(Date:11/27/2015)... Angeles, CA (PRWEB) , ... November 27, 2015 , ... ... study carried out by the University of Toronto and the University of British Columbia ... of hospitalizations for head injuries. The article explains that part of the reason for ...
(Date:11/27/2015)... ... November 27, 2015 , ... A team of Swiss doctors ... treat it. Surviving Mesothelioma has just posted the findings on the website. Click ... analyzed the cases of 136 mesothelioma patients who were treated with chemotherapy followed by ...
(Date:11/27/2015)... ... , ... Lizzie’s Lice Pickers just announced a special promotion that will run ... purchase of lice treatment product. In addition, customers will receive a complimentary head Check ... lice is a sure way to ruin the holidays, so we encourage all of ...
(Date:11/27/2015)... ... ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of its ... 3.7 billion people under the age of 50 – or 67% of the population - ... estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle Li, ...
(Date:11/27/2015)... ... ... A simply groundbreaking television series, "Voices in America", which is hosted by Hollywood legend, ... that are presently affecting Americans. Dedicated to providing the world with a wide variety ... consumers focus on, one episode at a time. , In the latest installment ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... 26 november 2015 AAIPharma Services ... geplande investering aan van ten minste $15,8 ... en het mondiale hoofdkantoor in ... resulteren in extra kantoorruimte en extra capaciteit ... groeiende behoeften van de farmaceutische en biotechnologische ...
(Date:11/26/2015)... , November 26, 2015 3D bioprinting ... 2022, according to a new report by Grand View Research ... Disease (CKD) which demands kidney transplantation is expected to boost ... effective substitute for organ transplantation. --> 3D bioprinting ... 2022, according to a new report by Grand View Research ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology: